Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 538

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1
Chunk 538
---
 hazard control and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply
with such laws and regulations now or in the future.

Regulation in Israel. In
order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained from the ethics committee
and general manager of the institution in which the clinical studies are scheduled to be conducted, as required under the Guidelines for
Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as
amended from time to time, and other applicable legislation. These regulations require authorization by the institutional ethics committee
and general manager as well as from the Israeli Ministry of Health, except in certain circumstances, and in the case of genetic trials,
special fertility trials and complex clinical trials, an additional authorization of the Ministry of Health’s overseeing ethics
committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived
from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must
ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information gathered
in the course of the clinical testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in
Israel, we are required to obtain authorization from the ethics committee and general manager of each institution in which we intend to
conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.

29

Corporate History

We were incorporated on April
24, 2015. On June 25, 2019, our name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc.

We have the following wholly owned
subsidiaries:

    -
    Beyond Air Ltd. (“BA Ltd.”), incorporated in Israel on May 1, 2011.

    -
    Beyond Air Australia Pty Ltd., incorporated on December 17, 2019 in Australia.

    -
    Beyond Air Ireland Limited, incorporated on March 5, 2020 in Ireland.

    We have 88.2% ownership in the following entity:

    -
    Jodheary Holdco 18 Limited, incorporated on March 24, 2023 in Ireland. In April 2023, its name was changed to Beyond Air (NO) Limited. In March 2024, its name was changed to NeuroNOS Ltd.

    NeuroNOS Ltd.